Avata planning Phase 3 CBD clinical trial of new formulation SAP-021
Avata Biosciences is gearing up for a Phase 3 clinical trial to test SAP-021, the company’s oral capsule formulation of cannabidiol — commonly abbreviated as CBD — that’s being developed as an alternative to Epidiolex, an oil-based cannabidiol solution that’s approved to reduce seizure frequency in people with…